Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2016, Article ID 2674954, 8 pages
http://dx.doi.org/10.1155/2016/2674954
Research Article

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma

1University of Alabama School of Medicine, Birmingham, AL 35233, USA
2Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA
3Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35249, USA
4Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35249, USA

Received 8 January 2016; Accepted 22 February 2016

Academic Editor: Manfred Wirth

Copyright © 2016 Christopher B. Baker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Comprehensive Cancer Network, Prostate Cancer Guidelines (Version 1.2015), 2015.
  2. A. Bill-Axelson, L. Holmberg, H. Garmo et al., “Radical prostatectomy or watchful waiting in early prostate cancer,” The New England Journal of Medicine, vol. 370, no. 10, pp. 932–942, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Warde, M. Mason, K. Ding et al., “Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial,” The Lancet, vol. 378, no. 9809, pp. 2104–2111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. C. Albertsen, J. A. Hanley, and J. Fine, “20-Year outcomes following conservative management of clinically localized prostate cancer,” The Journal of the American Medical Association, vol. 293, no. 17, pp. 2095–2101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Zhou, M.-H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D'Amico, “Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6992–6998, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. B. Eifler, Z. Feng, B. M. Lin et al., “An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011,” BJU International, vol. 111, no. 1, pp. 22–29, 2006. View at Publisher · View at Google Scholar
  7. I. M. Thompson, R. K. Valicenti, P. Albertsen et al., “Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline,” The Journal of Urology, vol. 190, no. 2, pp. 441–449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Roach III, G. Hanks, H. Thames Jr. et al., “Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference,” International Journal of Radiation Oncology, Biology, Physics, vol. 65, no. 4, pp. 965–974, 2006. View at Publisher · View at Google Scholar
  9. M. S. Cookson, G. Aus, A. L. Burnett et al., “Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes,” Journal of Urology, vol. 177, no. 2, pp. 540–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. P. Swanson, M. A. Hussey, C. M. Tangen et al., “Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2225–2229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Zapatero, F. Valcárcel, F. A. Calvo et al., “Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6561–6568, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Widmark, O. Klepp, A. Solberg et al., “Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial,” The Lancet, vol. 373, no. 9660, pp. 301–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. Horwitz, K. Bae, G. E. Hanks et al., “Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2497–2504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Zapatero, A. Guerrero, X. Maldonado et al., “High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial,” The Lancet Oncology, vol. 16, no. 3, pp. 320–327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. E. H. Ramahi, G. P. Swanson, M. W. Jackson, F. Du, and J. W. Basler, “High-grade prostate cancer: favorable results in the modern era regardless of initial treatment,” ISRN Oncology, vol. 2012, Article ID 596029, 6 pages, 2012. View at Publisher · View at Google Scholar
  16. J. M. Watkins, P. L. Watkins, T. A. Dufan, and N. Koleilat, “High-grade prostate adenocarcinoma (Gleason Score ≥8): survival and disease control following radical prostatectomy versus radiotherapy plus long-course hormone therapy,” Journal of Radiation Oncology, vol. 4, no. 3, pp. 277–282, 2015. View at Publisher · View at Google Scholar
  17. M. Bolla, G. Van Tienhoven, P. Warde et al., “External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study,” The Lancet Oncology, vol. 11, no. 11, pp. 1066–1073, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. B. H. Lee, A. S. Kibel, J. P. Ciezki et al., “Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence,” European Urology, vol. 67, no. 2, pp. 204–209, 2015. View at Publisher · View at Google Scholar
  19. M. E. Nielsen, D. V. Makarov, E. Humphreys, L. Mangold, A. W. Partin, and P. C. Walsh, “Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion—‘Nadir + 2’?” Urology, vol. 72, no. 2, pp. 389–393, 2008. View at Publisher · View at Google Scholar
  20. A. A. Aizer, J. B. Yu, J. W. Colberg, A. M. McKeon, R. H. Decker, and R. E. Peschel, “Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Stephenson, P. T. Scardino, J. A. Eastham et al., “Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy,” Journal of the National Cancer Institute, vol. 98, no. 10, pp. 715–717, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Abramowitz, T. Li, M. K. Buyyounouski et al., “The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer,” Cancer, vol. 112, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. J. Stephenson, M. W. Kattan, J. A. Eastham et al., “Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3973–3978, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Siddiqui, S. Rais-Bahrami, B. Turkbey et al., “Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer,” The Journal of the American Medical Association, vol. 313, no. 4, pp. 390–397, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. T. B. Dorff, T. W. Flaig, C. M. Tangen et al., “Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2040–2045, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. D'Amico, M.-H. Chen, A. A. Renshaw, M. Loffredo, and P. W. Kantoff, “Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial,” The Journal of the American Medical Association, vol. 299, no. 3, pp. 289–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. V. Pilepich, K. Winter, C. A. Lawton et al., “Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1285–1290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Roach III, K. Bae, J. Speight et al., “Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 585–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Briganti, F. K.-H. Chun, A. Salonia et al., “Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy,” Urology, vol. 69, no. 1, pp. 147–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Abdollah, G. Gandaglia, N. Suardi et al., “More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer,” European Urology, vol. 67, no. 2, pp. 212–219, 2015. View at Publisher · View at Google Scholar
  31. H. M. Sandler, C. Hu, S. A. Rosenthal et al., “A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521),” Journal of Clinical Oncology, vol. 33, supplement, abstract LBA5002, 2015. View at Google Scholar